Compare Li Auto Inc (LI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs BIO-TECHNE Corp — how do they compare? Li Auto Inc trades at $11.51 (market cap $10.71B), while BIO-TECHNE Corp trades at $72.47 (market cap $11.36B). The key difference: Li Auto Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and BIO-TECHNE Corp for 64 Days on average.
| LI | TECH | |
|---|---|---|
Market Cap | $10.71B | $11.36B |
Volume | 1,781,143 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $72.61 |
52-Week Low | $10.69 | $43.31 |
Typical Hold Time | 101 Days | 64 Days |
Enterprise Value | $139.58M | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.61, down 5.64% on the day and near 52-week lows amid delivery concerns. The technical picture is bearish with negative moving averages, while fundamentals show revenue declining from $144.5B in 2024 to $112.3B in 2025, though the company maintains a strong balance sheet with $112.8B cash. Recent Q2 2026 earnings missed expectations with a net loss of $0.25 per share, and September deliveries of 31,817 vehicles indicate volume moderation.
The outlook remains challenging with intense EV competition and margin pressure, but analyst consensus suggests 31% upside to the $15.18 price target. Key risks include execution on new model launches (Li i9, MEGA) and China's auto market slowdown, while the company's cash position provides buffer against near-term headwinds.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
